Article
Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells.
Molecular therapy : the journal of the American Society of Gene Therapy - 5 Apr 2017
MacLeod Daniel T, Antony Jeyaraj, Martin Aaron J, Moser Rachel J, Hekele Armin, Wetzel Keith J, Brown Audrey E, Triggiano Melissa A, Hux Jo Ann, Pham Christina D, Bartsevich Victor V, Turner Caitlin A, Lape Janel, Kirkland Samantha, Beard Clayton W, Smith Jeff, Hirsch Matthew L, Nicholson Michael G, Jantz Derek, McCreedy Bruce
Abstract excerpt
Adoptive cellular therapy using chimeric antigen receptor (CAR) T cell therapies have produced significant objective responses in patients with CD19+ hematological malignancies, including durable complete responses. Although the majority of clinical trials to date have used autologous patient cells as the starting material to generate CAR T cells, this strategy poses significant manufacturing challenges and, for...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.